Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Not all compounding pharmacies are equal. We track accreditations, testing standards, inspection history, and pricing transparency so you can choose with confidence.
In April 2026 the FDA removed 12 peptides — including BPC-157, TB-500, MOTS-c, and DSIP — from Category 2(the significant-safety-risk list). They sit in a regulatory gray zone, not yet authorized for compounding. The FDA's Pharmacy Compounding Advisory Committee meets July 23–24, 2026 to review nominations and make recommendations — the FDA issues any final rule later. A valid prescription from a licensed provider is required for any compounded peptide.
Showing 1–30 of 114 compounding pharmacies
Not all compounding pharmacies meet the same standards. The difference between a PCAB-accredited facility and an unaccredited one can mean the difference between a sterile, accurately dosed peptide and one that carries contamination or under-fill risk. Here is what to look for before you order.
A 503A pharmacy compounds medications based on individual patient prescriptions. A 503B outsourcing facility can compound in bulk without patient-specific prescriptions and is subject to FDA cGMP inspections. 503B facilities generally have stricter testing requirements and higher manufacturing standards, but 503A pharmacies with strong accreditations can be equally reliable.
The Pharmacy Compounding Accreditation Board (PCAB) is the gold standard for compounding pharmacy accreditation. PCAB accreditation means the pharmacy has passed a rigorous evaluation of its compounding practices, quality assurance procedures, and personnel training. Only a small percentage of compounding pharmacies carry PCAB accreditation.
USP <797> governs sterile compounding practices — cleanroom standards, beyond-use dating, environmental monitoring, and personnel training for sterile preparations. Peptides are sterile injectables, so USP 797 compliance is non-negotiable. USP <800> covers hazardous drug handling, which applies to some peptides depending on their classification.
Quality pharmacies test every batch for identity, purity, potency, sterility, and endotoxin before dispensing. Ask whether the pharmacy provides a Certificate of Analysis (COA) with each order, whether their testing is done in-house or at a third-party ISO 17025 lab, and whether they publish COAs proactively or only on request.
FDA inspection results (Form 483 findings) and state pharmacy board actions are public record. A pharmacy with recent unresolved 483 findings or board warnings deserves scrutiny. Our quality scores factor in inspection history, and we flag pharmacies with recent enforcement actions.
Compounded peptide pricing varies dramatically — the same peptide can cost 3–5x more at one pharmacy than another. Always compare price per milligram, not total vial cost, since vial sizes and concentrations differ. Use our to see side-by-side pricing from multiple pharmacies and research vendors.
PCAB, USP 795/797/800, state licenses, FDA 503A/503B registration
In-house vs. third-party testing, COA completeness, endotoxin testing
FDA inspection results, state board findings, recall history
List your pharmacy in our verified directory. Reach patients and prescribers who are actively looking for quality compounding pharmacies. Includes your quality score, accreditation badges, and pricing display.
A 503A pharmacy compounds medications on a patient-specific basis — each order requires a valid prescription from a licensed prescriber. A 503B outsourcing facility can produce compounded drugs in bulk without patient-specific prescriptions, is subject to FDA current Good Manufacturing Practice (cGMP) inspections, and can sell to facilities such as clinics and hospital outpatient departments. Both are federally regulated for quality and safety.
In April 2026 the FDA removed 12 peptides from Category 2 (the significant-safety-risk list), placing them in a gray zone that is neither Category 1 (503A authorized) nor Category 2: BPC-157, KPV, Thymosin Beta-4 (TB-500), MOTS-c, DSIP, Semax, and Epitalon (the seven now on the July 2026 PCAC docket), plus GHK-Cu, Melanotan II, LL-37, Dihexa, and PEG-MGF (under review by February 2027). None are on the Category 1 (503A) authorized list. The FDA's Pharmacy Compounding Advisory Committee (PCAC) meets July 23–24, 2026 to review nominations and make recommendations; the FDA issues any final rule later. (CJC-1295 and Ipamorelin remain in Category 2 pending separate litigation; Sermorelin was never in Category 2.) If and when added to the official Category 1 list, patients would obtain these peptides from a licensed compounding pharmacy with a valid prescription.
Yes. 503A compounding pharmacies require a valid prescription from a licensed prescriber — MD, DO, NP, PA, or equivalent — for each patient order. Telehealth providers can issue prescriptions remotely in most US states. The Disclosed Labs prescriber directory lists providers experienced with compounded peptides, including telehealth options.
Key accreditations for sterile compounding include: PCAB (Pharmacy Compounding Accreditation Board) — the gold standard for compounding quality; USP <797> compliance for sterile compounding practices; USP <800> compliance for hazardous drug handling; and NABP accreditation. For 503B outsourcing facilities, FDA cGMP compliance and a clean inspection history (no unresolved Form 483 findings) are essential.
This platform provides informational tools only, not medical advice. Consult a licensed provider. Pharmacy listings do not constitute endorsement by Disclosed Labs.
Published pricing, insurance acceptance, patient assistance programs
Verified patient reviews, response time, shipping quality
Composite score from all metrics above, updated regularly
Research peptide vendors sell peptides labeled 'for research use only' — they are not licensed to dispense to patients and their products are not subject to pharmaceutical manufacturing standards or prescription requirements. Compounding pharmacies are state-licensed and (for 503B) federally registered facilities that produce pharmaceutical-grade medications under a prescriber's order, subject to USP standards, quality testing, and FDA and state oversight. If peptides like BPC-157 and CJC-1295 are added to the FDA's Category 1 (503A) list, compounding pharmacies would become the appropriate licensed source for patients with a valid prescription.
Disclosed Labs